SA
Log In
SNY
OverviewIntelligenceChart
Next earnings: Jul 30, 2026 · Before open
Signal
Leaning Bearish1↓
Price
1→
Move→+0.02%Quiet session
Volume
1→
Volume→0.8× avgNormal activity
Technical
1↓
RSI↓RSI 50Momentum negative
PRICE
Prev Close
43.35
Open
43.35
Day Range43.10 – 43.54
43.10
43.54
52W Range43.10 – 55.29
43.10
55.29
2% of range
VOLUME & SIZE
Avg Volume
2.9M
FUNDAMENTALS
P/E Ratio
18.7x
EPS (TTM)
—
Div Yield
0.04%
Beta
0.45
Low vol
Quick Read
Trend—Insufficient MA data
Momentum
BULLISH
revenue +8% YoY · 72% gross margin
Valuation
FAIR
P/E 19x vs ~20x sector
Health
STRONG
CR 1.0 · FCF $15.69/sh
Strong Buy
Key MetricsTTM
Market Cap$89.03B
Revenue TTM$47.35B
Net Income TTM$7.55B
Free Cash Flow$8.28B
Gross Margin71.6%
Net Margin17.6%
Operating Margin25.1%
Return on Equity14.4%
Return on Assets8.1%
Debt / Equity0.27
Current Ratio1.01
EPS TTM$8.60
Alpha SignalsView Intelligence →

Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.

Health Radar
2 strong3 watch1 concern
55/100
Liquidity
1.01Watch
Leverage
0.27Strong
Coverage
28.0xStrong
ROE
14.4%Watch
ROIC
11.7%Watch
Cash
$7.7BConcern
ANALYST COVERAGE27 analysts
HOLD
▲ +17.6%upside to target
L $50.00
Med $51.00consensus
H $52.00
Buy
1452%
Hold
1141%
Sell
27%
14 Buy (52%)11 Hold (41%)2 Sell (7%)
Full report →
Stock Health
Composite Score
1 of 4 signals bullish
5/10
Technicals
●
RSI RangeRSI 50 — Bearish momentum
✗
Fundamentals
●
Last EarningsBeat estimates
✓
●
Analyst ConsensusHold
~
●
LiquidityCurrent Ratio 1.01
~

1 signal unavailable — limited data for this stock

Upcoming Events
EEarnings Report · Before OpenMay 7, 2026
Tomorrow
DEx-Dividend DateAug 4, 2026
In 90 days
PDividend PaymentSep 1, 2026
In 118 days
Research
Fundamentals→Financials→Analysts→Earnings→Growth→Key Metrics→Technical Analysis→Intelligence→
Technicals
Technical SetupMIXED
Technicals →

Trend

▼ DowntrendDeath Cross · 50D trails 200D by 3.7%

-6.5% vs SMA 50 · -10.0% vs SMA 200

Momentum

RSI49.7
Neutral territory
MACD+0.30
Above zero — bullish momentum · expanding
Market Position
Price Levels
52W High
$55.29+27.5%
EMA 200
$48.22+11.2%
EMA 50
$46.41+7.0%
Current
$43.36
52W Low
$43.10-0.6%
52-Week RangeNear 52-week low
$43.102th %ile$55.29
Earnings & Analysts

ANALYST ESTIMATES

Consensus of 8 analysts
Full estimates →
Analyst revisions:EPS↓ Revised DownRevenue↓ Revised Down

Analyst consensus estimates · Actuals replace estimates as reported

YearRevenue Est.Rev GthEPS Est.EPS GthRangeAnalysts
FY2025
$45.1B
$42.5B–$46.8B
—$3.86—
±2%
High8
FY2026(current)
$48.0B
$45.9B–$50.7B
▲ +6.4%$4.21▲ +9.1%
±3%
High8
FY2027
$51.0B
$46.3B–$54.1B
▲ +6.1%$4.49▲ +6.7%
±7%
High8
Range confidence:Tight (high)ModerateWide (low)
Earnings HistorySNY
Last 8Q
+4.6%avg beat
Beat 6 of 8 quartersMissed 2↑ Estimates rising
+8%
Q3'24
+16%
Q4'24
-1%
Q1'25
+4%
Q2'25
-6%
Q3'25
+6%
Q4'25
+6%
Q1'26
+4%
Q2'26
Beat
Miss
Estimate
Deeper color = bigger beat/miss
Analyst Activity
All ratings →
Analysts turning cautious
30d▲ 0▼ 1
90d▲ 0▼ 1
Exane BNP ParibasOutperform → Neutral
Apr 20
DOWNGRADE
UBSBuy → Neutral
Jan 16
DOWNGRADE
GuggenheimBuy → Neutral
Dec 9
DOWNGRADE
Morgan StanleyOverweight
Sep 8
UPGRADE
Deutsche BankHold → Buy
Sep 2
UPGRADE
Deutsche BankHold
Aug 12
UPGRADE
Financials
Dividends5.57% yield
+0.5% avg annual growth
Annual Yield5.57%
Annual Div.$1.7669
Est. Annual / Share$1.77
FrequencyAnnual
Q2'20
Q2'21
Q2'22
Q2'22
Q2'23
Q2'24
Q2'25
Q2'26

Dividend per payment — last 8 periods

INSTITUTIONAL OWNERSHIP

13-F Filings →
1
Mondrian Investment Partners LTD
5.0M▲
2
ENVESTNET ASSET MANAGEMENT INC
3.9M▲
3
EQUITY INVESTMENT CORP
2.7M▲
4
DAVENPORT & Co LLC
2.1M▲
5
Nuveen, LLC
1.9M▲
6
NICHOLAS COMPANY, INC.
1.5M▼
7
MANNING & NAPIER ADVISORS LLC
1.2M▲
8
Pictet Asset Management Holding SA
678K▲
News & Activity

SNY News

20 articles · 4h ago

About

Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. Originally, the corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo

Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
CEO
Paul Hudson
Country
France
Website
sanofi.com ↗
Olivier CharmeilExecutive Vice President of General Medicines
Roy PapatheodorouExecutive Vice President & General Counsel
François-Xavier RogerExecutive Vice President & Chief Financial Officer

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance